Comments
Loading...

BridgeBio Pharma Analyst Ratings

BBIONASDAQ
Logo brought to you by Benzinga Data
$32.26
At close: May 29 EDT
$33.50
1.243.84%
Pre-Market: 4:11 AM EDT
Consensus Rating1
Buy
Highest Price Target1
$95.00
Lowest Price Target1
$19.00
Consensus Price Target1
$49.11

BridgeBio Pharma Analyst Ratings and Price Targets | NASDAQ:BBIO | Benzinga

BridgeBio Pharma Inc has a consensus price target of $49.11 based on the ratings of 21 analysts. The high is $95 issued by Cantor Fitzgerald on February 21, 2025. The low is $19 issued by SVB Leerink on January 23, 2023. The 3 most-recent analyst ratings were released by Scotiabank, Piper Sandler, and UBS on April 30, 2025, respectively. With an average price target of $63.33 between Scotiabank, Piper Sandler, and UBS, there's an implied 89.05% upside for BridgeBio Pharma Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
2
Dec 24
3
Feb
2
Mar
3
Apr
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.8
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Scotiabank
Piper Sandler
UBS
HC Wainwright & Co.
Redburn Atlantic

1calculated from analyst ratings

Analyst Ratings for BridgeBio Pharma

Buy NowGet Alert
04/30/2025Buy Now64.18%Scotiabank
Greg Harrison49%
$52 → $55MaintainsSector OutperformGet Alert
04/30/2025Buy Now88.06%Piper Sandler
Biren Amin39%
$46 → $63MaintainsOverweightGet Alert
04/30/2025Buy Now114.93%UBS
Eliana Merle43%
$65 → $72MaintainsBuyGet Alert
04/15/2025Buy Now58.21%HC Wainwright & Co.
Raghuram Selvaraju42%
$49 → $53MaintainsBuyGet Alert
03/31/2025Buy Now49.25%Redburn Atlantic
Joshua Smith 37%
→ $50Initiates → BuyGet Alert
03/24/2025Buy Now49.25%JP Morgan
Anupam Rama56%
$44 → $50MaintainsOverweightGet Alert
02/21/2025Buy Now46.27%Citigroup
David Lebowitz53%
$45 → $49MaintainsBuyGet Alert
02/21/2025Buy Now183.58%Cantor Fitzgerald
Josh Schimmer52%
$95 → $95ReiteratesOverweight → OverweightGet Alert
02/21/2025Buy Now55.22%Scotiabank
Greg Harrison49%
$49 → $52MaintainsSector OutperformGet Alert
02/13/2025Buy Now46.27%HC Wainwright & Co.
Raghuram Selvaraju42%
$49 → $49ReiteratesBuy → BuyGet Alert
02/12/2025Buy Now46.27%Scotiabank
Greg Harrison49%
$48 → $49MaintainsSector OutperformGet Alert
12/23/2024Buy Now49.25%Evercore ISI Group
Cory Kasimov68%
$45 → $50MaintainsOutperformGet Alert
12/16/2024Buy Now46.27%HC Wainwright & Co.
Raghuram Selvaraju42%
$49 → $49ReiteratesBuy → BuyGet Alert
11/25/2024Buy Now43.28%Scotiabank
Greg Harrison49%
$45 → $48MaintainsSector OutperformGet Alert
11/25/2024Buy Now34.33%B of A Securities
Geoff Meacham61%
$42 → $45MaintainsBuyGet Alert
11/25/2024Buy Now46.27%HC Wainwright & Co.
Raghuram Selvaraju42%
$43 → $49MaintainsBuyGet Alert
11/15/2024Buy Now34.33%Scotiabank
Greg Harrison49%
$44 → $45MaintainsSector OutperformGet Alert
10/25/2024Buy Now28.36%HC Wainwright & Co.
Raghuram Selvaraju42%
$43 → $43ReiteratesBuy → BuyGet Alert
10/17/2024Buy Now37.31%Leerink Partners
Mani Foroohar47%
$47 → $46MaintainsOutperformGet Alert
10/16/2024Buy Now31.34%Scotiabank
Greg Harrison49%
→ $44Initiates → Sector OutperformGet Alert
10/03/2024Buy NowOppenheimer
Leland Gershell67%
Initiates → PerformGet Alert
10/02/2024Buy Now28.36%HC Wainwright & Co.
Raghuram Selvaraju42%
$43 → $43ReiteratesBuy → BuyGet Alert
09/30/2024Buy Now28.36%HC Wainwright & Co.
Raghuram Selvaraju42%
$43 → $43ReiteratesBuy → BuyGet Alert
09/17/2024Buy Now28.36%HC Wainwright & Co.
Raghuram Selvaraju42%
$43 → $43ReiteratesBuy → BuyGet Alert
09/16/2024Buy Now108.96%Cantor Fitzgerald
Josh Schimmer52%
$70 → $70ReiteratesOverweight → OverweightGet Alert
09/16/2024Buy Now28.36%HC Wainwright & Co.
Raghuram Selvaraju42%
$43 → $43ReiteratesBuy → BuyGet Alert
09/11/2024Buy Now25.37%B of A Securities
Geoff Meacham61%
$42 → $42MaintainsBuyGet Alert
09/09/2024Buy Now108.96%Cantor Fitzgerald
Josh Schimmer52%
$70 → $70ReiteratesOverweight → OverweightGet Alert
09/04/2024Buy Now37.31%Piper Sandler
Biren Amin39%
→ $46Initiates → OverweightGet Alert
09/03/2024Buy Now28.36%HC Wainwright & Co.
Raghuram Selvaraju42%
$43 → $43ReiteratesBuy → BuyGet Alert
08/27/2024Buy Now28.36%HC Wainwright & Co.
Raghuram Selvaraju42%
$43 → $43ReiteratesBuy → BuyGet Alert
08/22/2024Buy Now28.36%HC Wainwright & Co.
Raghuram Selvaraju42%
$43 → $43ReiteratesBuy → BuyGet Alert
08/07/2024Buy Now28.36%JP Morgan
Anupam Rama56%
$46 → $43MaintainsOverweightGet Alert
08/07/2024Buy Now34.33%Evercore ISI Group
Cory Kasimov68%
$50 → $45MaintainsOutperformGet Alert
08/05/2024Buy Now28.36%HC Wainwright & Co.
Raghuram Selvaraju42%
$43 → $43ReiteratesBuy → BuyGet Alert
07/01/2024Buy Now108.96%Cantor Fitzgerald
Josh Schimmer52%
$70 → $70ReiteratesOverweight → OverweightGet Alert
06/25/2024Buy Now25.37%B of A Securities
Geoff Meacham61%
$50 → $42MaintainsBuyGet Alert
06/20/2024Buy Now28.36%HC Wainwright & Co.
Raghuram Selvaraju42%
$43 → $43ReiteratesBuy → BuyGet Alert
06/05/2024Buy Now28.36%HC Wainwright & Co.
Raghuram Selvaraju42%
$43 → $43ReiteratesBuy → BuyGet Alert
05/30/2024Buy Now28.36%HC Wainwright & Co.
Raghuram Selvaraju42%
$43 → $43ReiteratesBuy → BuyGet Alert
05/28/2024Buy Now108.96%Cantor Fitzgerald
Josh Schimmer52%
$70 → $70ReiteratesOverweight → OverweightGet Alert
05/28/2024Buy Now40.3%UBS
Eliana Merle43%
$51 → $47MaintainsBuyGet Alert
05/20/2024Buy Now28.36%HC Wainwright & Co.
Raghuram Selvaraju42%
$47 → $43MaintainsBuyGet Alert
05/14/2024Buy Now49.25%Evercore ISI Group
Cory Kasimov68%
→ $50Initiates → OutperformGet Alert
03/20/2024Buy Now34.33%JP Morgan
Anupam Rama56%
$35 → $45MaintainsOverweightGet Alert
03/19/2024Buy Now108.96%Cantor Fitzgerald
Josh Schimmer52%
$60 → $70MaintainsOverweightGet Alert
03/11/2024Buy Now79.1%Cantor Fitzgerald
Josh Schimmer52%
$50 → $60MaintainsOverweightGet Alert
03/05/2024Buy Now58.21%Mizuho
Salim Syed43%
$60 → $53MaintainsBuyGet Alert
03/04/2024Buy Now40.3%HC Wainwright & Co.
Raghuram Selvaraju42%
$47 → $47ReiteratesBuy → BuyGet Alert
02/23/2024Buy Now37.31%Citigroup
David Lebowitz53%
$42 → $46MaintainsBuyGet Alert
01/31/2024Buy Now10.45%BMO Capital
Kostas Biliouris34%
→ $37Initiates → Market PerformGet Alert
01/29/2024Buy Now40.3%HC Wainwright & Co.
Raghuram Selvaraju42%
$22 → $47MaintainsBuyGet Alert
01/22/2024Buy Now49.25%Cantor Fitzgerald
Josh Schimmer52%
$50 → $50ReiteratesOverweight → OverweightGet Alert
11/07/2023Buy Now25.37%Citigroup
David Lebowitz53%
→ $42Initiates → BuyGet Alert
10/24/2023Buy Now49.25%Cantor Fitzgerald
Josh Schimmer52%
→ $50Initiates → OverweightGet Alert
08/28/2023Buy Now79.1%Mizuho
Salim Syed43%
→ $60ReiteratesBuy → BuyGet Alert
08/17/2023Buy Now13.43%JP Morgan
Anupam Rama56%
$42 → $38MaintainsOverweightGet Alert
08/14/2023Buy Now79.1%Mizuho
Salim Syed43%
$50 → $60MaintainsBuyGet Alert
07/18/2023Buy Now49.25%Goldman Sachs
Paul Choi58%
$29 → $50MaintainsBuyGet Alert
07/18/2023Buy Now37.31%Raymond James
Dane Leone45%
$29 → $46MaintainsOutperformGet Alert
07/18/2023Buy Now-1.49%Jefferies
Eun Yang33%
$24 → $33DowngradeBuy → HoldGet Alert
05/08/2023Buy Now-13.43%Mizuho
Salim Syed43%
$23 → $29MaintainsBuyGet Alert
04/19/2023Buy Now19.4%Evercore ISI Group
Josh Schimmer52%
→ $40Initiates → OutperformGet Alert
04/13/2023Buy Now-19.4%SVB Securities
Mani Foroohar47%
$25 → $27MaintainsOutperformGet Alert
03/07/2023Buy Now-31.34%JP Morgan
Anupam Rama56%
$18 → $23MaintainsOverweightGet Alert
03/07/2023Buy Now-16.42%Goldman Sachs
Paul Choi58%
$20 → $28MaintainsBuyGet Alert
03/07/2023Buy Now-13.43%Raymond James
Dane Leone45%
$17 → $29MaintainsOutperformGet Alert
02/06/2023Buy NowCowen & Co.
Tyler Van Buren45%
Initiates → OutperformGet Alert
01/23/2023Buy Now-43.28%SVB Leerink
Mani Foroohar47%
$23 → $19MaintainsOutperformGet Alert
11/18/2022Buy Now-43.28%JP Morgan
Anupam Rama56%
$20 → $19MaintainsOverweightGet Alert
08/24/2022Buy Now-31.34%Mizuho
Salim Syed43%
$25 → $23MaintainsBuyGet Alert
07/26/2022Buy Now-10.45%SVB Leerink
Mani Foroohar47%
$27 → $30MaintainsOutperformGet Alert

FAQ

Q

What is the target price for BridgeBio Pharma (BBIO) stock?

A

The latest price target for BridgeBio Pharma (NASDAQ:BBIO) was reported by Scotiabank on April 30, 2025. The analyst firm set a price target for $55.00 expecting BBIO to rise to within 12 months (a possible 64.18% upside). 40 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for BridgeBio Pharma (BBIO)?

A

The latest analyst rating for BridgeBio Pharma (NASDAQ:BBIO) was provided by Scotiabank, and BridgeBio Pharma maintained their sector outperform rating.

Q

When was the last upgrade for BridgeBio Pharma (BBIO)?

A

There is no last upgrade for BridgeBio Pharma

Q

When was the last downgrade for BridgeBio Pharma (BBIO)?

A

The last downgrade for BridgeBio Pharma Inc happened on July 18, 2023 when Jefferies changed their price target from $24 to $33 for BridgeBio Pharma Inc.

Q

When is the next analyst rating going to be posted or updated for BridgeBio Pharma (BBIO)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BridgeBio Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BridgeBio Pharma was filed on April 30, 2025 so you should expect the next rating to be made available sometime around April 30, 2026.

Q

Is the Analyst Rating BridgeBio Pharma (BBIO) correct?

A

While ratings are subjective and will change, the latest BridgeBio Pharma (BBIO) rating was a maintained with a price target of $52.00 to $55.00. The current price BridgeBio Pharma (BBIO) is trading at is $33.50, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch